YIR-821

CAS No. 1883372-91-5

YIR-821( YIR821 )

Catalog No. M12924 CAS No. 1883372-91-5

YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    YIR-821
  • Note
    Research use only, not for human use.
  • Brief Description
    YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM).
  • Description
    YIR-821 is a small-molecule CD4 mimic that acts as a highly potent HIV entry inhibitor with IC50 of 2.8 uM against YTA48P virus with no significant cytotoxicity (CC50>200 uM); A useful lead compound for the further development of HIV-1 entry inhibitors and could potentially be useful for co-administration with neutralizing antibodies for the treatment of HIV infection and AIDS.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    YIR821
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1883372-91-5
  • Formula Weight
    534.102
  • Molecular Formula
    C26H40ClN7O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N1-(4-chlorophenyl)-N2-(1-(2-(5-guanidinopentanamido)ethyl)-1-azaspiro[5.5]undecan-4-yl)oxalamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ohashi N, et al. ChemMedChem. 2016 Apr 19;11(8):940-6.
molnova catalog
related products
  • ST7612AA1

    ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo.

  • Nelfinavir mesylate

    A potent and orally bioavailable HIV-1 protease inhibitor with Ki of 2 nM; exhibits an antiviral EC50 of 30 nM in HIV-1 strain RF-infected CEM-SS cells.

  • Pirmitegravir

    Pirmitegravir (STP0404) is a potent and selective inhibitor of allosteric integrase (ALLINI) targeting the LEDGF/p75 binding site. Pirmitegravir inhibits PBMC.